Being able to detect cancers early can substantially improve survival, but most early detection tests for cancer rely on expensive and sophisticated molecular techniques that might be difficult to implement in resource strapped environments. Two new studies published last week attempt to overcome this problem.
Fochon Biosciences Ltd. has disclosed mitogen-activated protein kinase (ERK) inhibitors, particularly ERK1 and/or ERK2 reported to be useful for the treatment of cancer.
Immunos Therapeutics AG has received full ethical institutional approval from the Human Research Ethics Committee (HREC) and regulatory approval from the Australian Therapeutic Goods Administration (TGA) to conduct a phase I trial of its lead program IOS-1002 in Australia.
Major histocompatibility complex class I (MHC-I) gene promoters are bivalently modified during development, which can be exploited in cancer cells to silence MHC-I expression and evade CD8+ T cells; in cells that exhibit bivalent modification of MHC-I genes, lower levels of cell surface MHC-I can be induced either by PRC2 inhibition or exposing the cells to interferon γ (IFNγ) in conjunction with polycomb inhibition to allow a permissive chromatin status.
Pancreatic cancer is an exceptionally lethal cancer that is notoriously treatment resistant, in part due to poor vascularization in the tumor microenvironment. Investigators working at the Moores Cancer Center at the University of California, San Diego (UCSD), reported in the Jan. 16, 2023, issue of Nature Cell Biology on the discovery of a pathway that was initiated by isolation stresses (e.g., hypoxia, nutrient deprivation, and/or lack of extracellular matrix, ECM) leading to this cellular transformation in the tumor-initiating pancreatic cancer cell.
University of Maryland has identified proteolysis targeting chimeras (PROTACs) acting as apoptosis regulator Bcl-2, Bcl-2-like protein 1 (BCL2L1) and induced myeloid leukemia cell differentiation protein Mcl-1 degradation inducers.
Carrick Therapeutics UK Ltd. has synthesized cyclin-dependent kinase 12 (CDK12) and/or cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of autoimmune diseases, cardiovascular disorders, fragile X syndrome, muscular dystrophy, neurodegeneration, renal disorders and cancer.
Scorpion Therapeutics Inc. has disclosed urea derivatives acting as phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.
Researchers from Guangzhou University of Chinese Medicine have presented preclinical results on a three-component vaccine, MPLA-Tn-KRN7000, as a tumor immunotherapeutic.
Poolbeg Pharma plc is expanding its evaluation of POLB-001 into oncology after findings indicated POLB-001's potential to dampen the pro-inflammatory cytokine release syndrome (CRS) in patients receiving chimeric antigen receptor (CAR) T-cell therapies for cancer.
RSS
